Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?

IRWD expects Linzess demand to accelerate, driving a bullish 2026 outlook with revenue growth, higher profits and expanding adoption.

Zacks Investment Research • Feb 5, 2026

4 Stocks Trading Near 52-Week High With More Upside Potential

Stocks like IPGP, DG, IRWD and SAIC are seeing price strength and have a high chance of carrying the momentum forward.

Zacks Investment Research • Jan 23, 2026

Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating

The pharmaceutical sector is famously volatile, usually driven by the binary outcomes of clinical trials. A drug either works, sending the stock to the moon, or it fails, causing a crash.

MarketBeat • Jan 7, 2026

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.

Zacks Investment Research • Jan 7, 2026

Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026

IRWD shares jump on upbeat 2026 revenue guidance amid rising Linzess demand in the United States. The company also provides a key pipeline update.

Zacks Investment Research • Jan 5, 2026

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced financial guidance for full year 2026. “Throughout 2025, we made significant progress in maximizing LINZESS while delivering sustained profits and cash flows in an effort to strengthen our financial position and maintain compliance with debt covenants over the coming.

Business Wire • Jan 2, 2026

Why Is Ironwood (IRWD) Up 24.9% Since Last Earnings Report?

Ironwood (IRWD) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Dec 10, 2025

IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick?

Ironwood and Puma Biotechnology are advancing therapies for gastrointestinal disorders and cancer, respectively. Rising sales of key drugs fuel 2026 prospects.

Zacks Investment Research • Nov 27, 2025

Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025

Ironwood Pharmaceuticals (IRWD) remains undervalued despite a failed $1bn Vectiv Bio acquisition and subsequent stock plunge, with Linzess providing strong recurring revenue. IRWD's apraglutide Phase 3 trial met primary endpoints but failed to surpass Takeda's Gattex, prompting the FDA to require another confirmatory study before approval. Linzess sales are robust, with Q3 2025 sales up 40% year-on-year and new pediatric approval, but looming 2029 patent expiry poses a long-term risk.

Seeking Alpha • Nov 26, 2025

Can Linzess Continue to Aid IRWD's Top Line After a Strong Q3?

Ironwood gains momentum as rising U.S. demand for Linzess drives strong profit growth during the third quarter.

Zacks Investment Research • Nov 21, 2025